Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).

<h4>Background</h4>Tata MD CHECK SARS-CoV-2 kit 1.0, a CRISPR based reverse transcription PCR (TMC-CRISPR) test was approved by Indian Council of Medical Research (ICMR) for COVID-19 diagnosis in India. To determine the potential for rapid roll-out of this test, we conducted performance...

Full description

Bibliographic Details
Main Authors: Shubhada Shenai, Gita Nataraj, Minal Jinwal, Akhil S Thekke Purakkal, Rajashree Sen, Nayana Ingole, Trupti Mathure, Sanjay Sarin, Sarabjit S Chadha
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0291269
_version_ 1827812031624904704
author Shubhada Shenai
Gita Nataraj
Minal Jinwal
Akhil S Thekke Purakkal
Rajashree Sen
Nayana Ingole
Trupti Mathure
Sanjay Sarin
Sarabjit S Chadha
author_facet Shubhada Shenai
Gita Nataraj
Minal Jinwal
Akhil S Thekke Purakkal
Rajashree Sen
Nayana Ingole
Trupti Mathure
Sanjay Sarin
Sarabjit S Chadha
author_sort Shubhada Shenai
collection DOAJ
description <h4>Background</h4>Tata MD CHECK SARS-CoV-2 kit 1.0, a CRISPR based reverse transcription PCR (TMC-CRISPR) test was approved by Indian Council of Medical Research (ICMR) for COVID-19 diagnosis in India. To determine the potential for rapid roll-out of this test, we conducted performance characteristic and an operational feasibility assessment (OFA) at a tertiary care setting.<h4>Intervention</h4>The study was conducted at an ICMR approved COVID-19 RT-PCR laboratory of King Edward Memorial (KEM) hospital, Mumbai, India. The TMC-CRISPR test was evaluated against the gold-standard RT-PCR test using the same RNA sample extracted from fresh and frozen clinical specimens collected from COVID-19 suspects for routine diagnosis. TMC-CRISPR results were determined manually and using the Tata MD CHECK application. An independent agency conducted interviews of relevant laboratory staff and supervisors for OFA.<h4>Results</h4>Overall, 2,332 (fresh: 2,121, frozen: 211) clinical specimens were analysed of which, 140 (6%) were detected positive for COVID-19 by TMC-CRISPR compared to 261 (11%) by RT-PCR. Overall sensitivity and specificity of CRISPR was 44% (95% CI: 38.1%-50.1%) and 99% (95% CI: 98.2%-99.1%) respectively when compared to RT-PCR. Discordance between TMC-CRISPR and RT-PCR results increased with increasing Ct values and corresponding decreasing viral load (range: <20% to >85%). In the OFA, all participants indicated no additional requirements of training to set up RT PCR. However, extra post-PCR steps such as setting up the CRISPR reaction and handling of detection strips were time consuming and required special training. No significant difference was observed between manual and mobile app-based readings. However, issues such as erroneous results, difficulty in interpretation of faint bands, internet connectivity, data safety and security were highlighted as challenges with the app-based readings.<h4>Conclusion</h4>The evaluated version-Tata MD CHECK SARS-CoV-2 kit 1.0 of TMC-CRISPR test cannot be considered as an alternative to the RT-PCR. There is a definite scope for improvement in this assay.
first_indexed 2024-03-11T23:13:38Z
format Article
id doaj.art-96ef887c715244b281febcb41d06c7bc
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-03-11T23:13:38Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-96ef887c715244b281febcb41d06c7bc2023-09-21T05:32:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01189e029126910.1371/journal.pone.0291269Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).Shubhada ShenaiGita NatarajMinal JinwalAkhil S Thekke PurakkalRajashree SenNayana IngoleTrupti MathureSanjay SarinSarabjit S Chadha<h4>Background</h4>Tata MD CHECK SARS-CoV-2 kit 1.0, a CRISPR based reverse transcription PCR (TMC-CRISPR) test was approved by Indian Council of Medical Research (ICMR) for COVID-19 diagnosis in India. To determine the potential for rapid roll-out of this test, we conducted performance characteristic and an operational feasibility assessment (OFA) at a tertiary care setting.<h4>Intervention</h4>The study was conducted at an ICMR approved COVID-19 RT-PCR laboratory of King Edward Memorial (KEM) hospital, Mumbai, India. The TMC-CRISPR test was evaluated against the gold-standard RT-PCR test using the same RNA sample extracted from fresh and frozen clinical specimens collected from COVID-19 suspects for routine diagnosis. TMC-CRISPR results were determined manually and using the Tata MD CHECK application. An independent agency conducted interviews of relevant laboratory staff and supervisors for OFA.<h4>Results</h4>Overall, 2,332 (fresh: 2,121, frozen: 211) clinical specimens were analysed of which, 140 (6%) were detected positive for COVID-19 by TMC-CRISPR compared to 261 (11%) by RT-PCR. Overall sensitivity and specificity of CRISPR was 44% (95% CI: 38.1%-50.1%) and 99% (95% CI: 98.2%-99.1%) respectively when compared to RT-PCR. Discordance between TMC-CRISPR and RT-PCR results increased with increasing Ct values and corresponding decreasing viral load (range: <20% to >85%). In the OFA, all participants indicated no additional requirements of training to set up RT PCR. However, extra post-PCR steps such as setting up the CRISPR reaction and handling of detection strips were time consuming and required special training. No significant difference was observed between manual and mobile app-based readings. However, issues such as erroneous results, difficulty in interpretation of faint bands, internet connectivity, data safety and security were highlighted as challenges with the app-based readings.<h4>Conclusion</h4>The evaluated version-Tata MD CHECK SARS-CoV-2 kit 1.0 of TMC-CRISPR test cannot be considered as an alternative to the RT-PCR. There is a definite scope for improvement in this assay.https://doi.org/10.1371/journal.pone.0291269
spellingShingle Shubhada Shenai
Gita Nataraj
Minal Jinwal
Akhil S Thekke Purakkal
Rajashree Sen
Nayana Ingole
Trupti Mathure
Sanjay Sarin
Sarabjit S Chadha
Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).
PLoS ONE
title Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).
title_full Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).
title_fullStr Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).
title_full_unstemmed Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).
title_short Performance characteristics and operational feasibility assessment of a CRISPR based tata MD CHECK diagnostic test for SARS-CoV-2 (COVID-19).
title_sort performance characteristics and operational feasibility assessment of a crispr based tata md check diagnostic test for sars cov 2 covid 19
url https://doi.org/10.1371/journal.pone.0291269
work_keys_str_mv AT shubhadashenai performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT gitanataraj performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT minaljinwal performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT akhilsthekkepurakkal performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT rajashreesen performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT nayanaingole performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT truptimathure performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT sanjaysarin performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19
AT sarabjitschadha performancecharacteristicsandoperationalfeasibilityassessmentofacrisprbasedtatamdcheckdiagnostictestforsarscov2covid19